Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN: 20 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
20
Total FAERS Reports
0
Deaths Reported
2
Hospitalizations
20
As Primary/Secondary Suspect
1
Life-Threatening
2
Disabilities
Sanofi Vaccines US Inc.
Manufacturer

Drug Class: Actively Acquired Immunity [PE] · Manufacturer: Sanofi Vaccines US Inc. ·

First Report: 20150406 · Latest Report: 20240519

What Are the Most Common SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN Side Effects?

#1 Most Reported
Product storage error
8 reports (40.0%)
#2 Most Reported
Rhabdomyolysis
3 reports (15.0%)
#3 Most Reported
Pyrexia
2 reports (10.0%)

All SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Product storage error 8 40.0% 0 0

Who Reports SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN Side Effects? Age & Gender Data

Gender: 37.5% female, 62.5% male. Average age: 53.9 years. Most reports from: US. View detailed demographics →

Is SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN Getting Safer? Reports by Year

YearReportsDeathsHosp.
2015 2 0 2
2018 1 0 0
2020 3 0 0
2022 1 0 0
2024 4 0 0

View full timeline →

What Is SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN Used For?

IndicationReports
Immunisation 11

Other Drugs in Same Class: Actively Acquired Immunity [PE]

Official FDA Label for SALMONELLA TYPHI TY2 VI POLYSACCHARIDE ANTIGEN

Official prescribing information from the FDA-approved drug label.